ArticleAlimentary pharmacology & therapeutics2026
Incidence of Hepatitis B Virus Reactivation in Patients Treated With Immunosuppressive and Chemotherapeutic Agents.
Article in Alimentary pharmacology & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Incidence of Hepatitis B Virus Reactivation in Patients Treated With Immunosuppressive and Chemotherapeutic Agents.Alimentary pharmacology & therapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundData on the incidence of hepatitis B virus reactivation (HBVr) remain limited. In Japan, patients who are HBsAg-negative and anti-HBc-positive with undetectable HBV DNA are monitored without antiviral prophylaxis, allowing the estimation of HBVr incidence.
methodsUsing administrative claims data from Japan (2008-2022), we included patients receiving immunosuppressive or chemotherapeutic agents who were HBV DNA-negative at baseline, underwent at least two HBV DNA tests, and did not receive antiviral therapy. HBVr incidence was estimated and stratified according to AGA guideline-based risk categories.
resultsWe analysed 9422 patients. In the high-risk category, HBVr incidence was 52.3 per 1000 person-years (PY) (95% CI: 37.7-70.7) after anti-CD20 therapy and 46.5 per 1000 PY (95% CI: 15.1-108.5) after other high-risk agents. In the moderate-risk category, incidence was 21.0 per 1000 PY (95% CI: 8.4-43.2) after anthracycline derivatives, 12.1 per 1000 PY (95% CI: 4.9-25.0) after tyrosine kinase inhibitors, and 21.0 per 1000 PY (95% CI: 11.5-35.2) after moderate- to high-dose corticosteroids for ≥ 4 weeks. Low-dose or short-term corticosteroids were also associated with HBVr (12.4 per 1000 PY; 95% CI: 9.0-16.6). HBVr also occurred at 12.5 per 1000 PY (95% CI: 2.6-36.6) following other uncertain-risk immunosuppressive agents, including calcineurin inhibitors.
conclusionsHBVr incidence was quantified across a broad range of immunosuppressive and chemotherapeutic therapies, including those with previously limited incidence data. The observed incidence patterns were broadly consistent with current guideline-based risk stratification, while also highlighting measurable risk in some therapies traditionally considered lower risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.